HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

L’Oréal Partners With Microalgae Biotech For New Cosmetic Actives

Executive Summary

French firms L’Oréal and Microphyt partner to drive development of cosmetic solutions based on the latter’s patented, low-carbon process for cultivating microalgae. Already, Microphyt markets three cosmetic ingredients based on microalgae bioactives for enhanced skin vitality and resilience.

You may also be interested in...



L’Oreal Says Makeup Will Be Back, But ‘Health Is The Future Of Beauty’

Dermocosmetics was L’Oreal’s biggest growth story in 2020, benefiting from shifting consumer priorities during the COVID crisis and reinvigorated faith in the recommendations of healthcare professionals. Makeup sales tanked, but that could well reverse with the advent of another Roaring Twenties post-pandemic, L’Oreal leadership suggests.

Over The Counter 1 March 2024: The Emerging Benefits Of ‘Beauty-From-Within,’ Featuring Kenvue’s Paul LaTerra

In this episode of Over the Counter, HBW Insight speaks to Paul LaTerra, Director, R&D, Global Hair and Scalp for Kenvue, a New Jersey-based consumer health company that markets skin care brands Neutrogena, Aveeno and Lubriderm. We discuss growth of the beauty-from-within supplements market, how the products complement topical skin care and hair formulas and the growing body of research demonstrating significant skin and hair health benefits. 

IFF’s New CEO: Commercial Execution Strategy Will Get Biz Back On Track

Under CEO Erik Fyrwald, IFF is committed to improving commercial execution across its four businesses after five years of overall underperformance.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153168

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel